Telehealth Hormone Therapy Clinics: The Rules That Apply

A telehealth hormone therapy clinic has to treat testosterone and the other hormones differently. Testosterone is an anabolic steroid in Schedule III of the Controlled Substances Act, so every telemedicine prescription runs through DEA registration in the patient's state, DEA's telemedicine rules, and state controlled-substance law. Estrogen, progesterone and thyroid hormones are not controlled, but compounded versions, marketing claims, lab monitoring and state limits on who may be treated still apply. The clinic setup below covers both.

This is operational guidance, not legal or clinical advice.

What applies to testosterone?

• Schedule III. Anabolic steroids, including testosterone and its esters, are listed in Schedule III (21 CFR 1308.13(f)). Each prescriber needs a DEA registration in each state where patients are located, plus any state controlled-substance registration.
• DEA telemedicine rules. The Ryan Haight Act (21 U.S.C. 829(e)) generally requires an in-person evaluation before prescribing a controlled substance by means of the internet, with exceptions. DEA's fourth temporary extension (90 FR 61301) allows DEA-registered practitioners to prescribe Schedule II through V drugs by telemedicine without a prior in-person evaluation through December 31, 2026. DEA proposed a Special Registration for Telemedicine in January 2025; it is not final, and the proposed terms treated Schedule III through V drugs differently from Schedule II. Build a plan for both outcomes. See testosterone by telehealth and our DEA telemedicine rules hub.
• PDMP. Many states require prescribers to check the prescription drug monitoring program before prescribing controlled substances, with triggers that differ by state and drug. See PDMP checks for telehealth prescribers.
• Pharmacy. The dispensing pharmacy must hold a DEA registration and the license or permit each state requires, and carries its own corresponding responsibility for the prescription under 21 CFR 1306.04(a).

What applies to estrogen, progesterone and thyroid hormones?

• Not controlled, so DEA registration is not required for them, but state telehealth rules on establishing the relationship and prescribing still apply.
• Compounded hormones are not approved by FDA and have not been reviewed by FDA for safety, effectiveness or quality. Marketing must not imply otherwise, and claims that compounded "bioidentical" hormones are safer or more effective than approved products need substantiation that is rarely available. Section 502(bb) of the Food, Drug, and Cosmetic Act deems a compounded drug misbranded if its advertising or promotion is false or misleading in any particular.
• The 503A copy rule applies here too: a 503A pharmacy may not regularly compound drugs that are essentially copies of commercially available products, except where the prescriber determines a change makes a significant difference for the patient (21 U.S.C. 353a(b)).

Which state rules matter?

• Whether an asynchronous or audio-only visit can establish the relationship. See establishing a patient relationship by telehealth.
• State controlled-substance limits on anabolic steroids, which some states regulate beyond federal law.
• Restrictions on hormone therapy for minors, which a number of states have enacted, and which vary in scope and in whether they reach out-of-state clinicians treating residents.
• Consent requirements, and any specific consent for particular hormone treatments.
• State consumer health data laws. Washington's My Health My Data Act lists gender-affirming care information and reproductive or sexual health information among the categories of consumer health data. See the My Health My Data Act.

Which elements belong in the clinical protocol?

• Baseline labs before the first prescription, and monitoring labs at defined intervals, as the drug's labeling and your medical director's protocol require. A lab partner that reaches every state you serve is essential. See lab partners for telehealth.
• Diagnostic criteria for starting therapy, documented in the chart.
• Contraindications and the conditions that require in-person evaluation.
• Follow-up visits with a clinician at set intervals; no refills without review.
• Criteria for dose changes and for stopping therapy.

Where do hormone clinics get into trouble?

• Prescribing on symptoms alone, without lab confirmation the protocol calls for.
• Prescribing to patients in states where the clinician lacks a license or DEA registration. Location capture at every visit prevents this. See patient location verification.
• Marketing that promises energy, performance or anti-aging outcomes without substantiation, or that presents compounded products as approved or superior.
• Pharmacy arrangements with payments tied to prescription volume.
• Tracking pixels on intake pages that reveal hormone therapy interest to ad platforms.

DEA filings for prescribers are handled by our sister sites for physicians, nurse practitioners and PAs. Our DEA Telemedicine Readiness review ($1,450) prepares the prescribing side for January 1, 2027. See pricing.